Work

Safety and Efficacy of Frexalimab from the Phase 2 Open-label Extension in Participants with Relapsing Multiple Sclerosis: 2-year Results (S3.006)

Year: 2025

Type: article

Source: Neurology

DOI: 10.1212/wnl.0000000000208742

Authors: Patrick Vermersch, Cristina Granziera, Yang Mao-Draayer, Gary Cutter, Oleksandr Kalbus, Ivan Staikov, Michal Dufek, Xavier Montalban, Stephen Krieger, Stephane Saubadu, Xiaodong Luo, Brendan Smyth, Biljana Djukic, Philippe Truffinet, Erik Wallstroem, Gavin Giovannoni

Institutions: Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Neurosciences & Cognition, University of Basel, University Hospital of Basel, Oklahoma Medical Research Foundation, University of Alabama at Birmingham, Dnipro State Medical University, Tokuda Hospital, Acibadem City Clinic, Masaryk University, St. Anne's University Hospital Brno, Vall d'Hebron Hospital Universitari, Icahn School of Medicine at Mount Sinai, Sanofi (France), Sanofi (United States), Queen Mary University of London

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409222256

FWCI:

Cites:

Cited by:

Related to: 10